

(5) Respondent is required to undergo random drug screening at his own expense not less than one time per month, and is required to forward the results of the drug screens to the DEA Louisville Resident Office.

Accordingly, the Acting Deputy Administrator of the Drug Enforcement Administration, pursuant to the authority vested in him by 21 U.S.C. 823 and 28 CFR 0.100(b) and 0.104, hereby orders that the application, submitted by Roger McAlpin, D.M.D., for a DEA Certificate of Registration be, and it hereby is, granted in Schedules III non-narcotic, IV and V subject to the above described restrictions. This order is effective March 24, 1997.

Dated: February 10, 1996.  
James S. Milford,  
*Acting Deputy Administrator.*  
[FR Doc. 97-4345 Filed 2-20-97; 8:45 am]  
BILLING CODE 4410-09-M

**Manufacturer of Controlled Substances; Application**

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 13, 1997, Noramco of Delaware, Inc., Division of McNeilab, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Morphine (9300) .....	II
Codeine (9050) .....	II
Thebaine (9333) .....	II
Hydrocodone (9193) .....	II
Oxycodone (9143) .....	II

The firm plans to manufacture the listed controlled substances for distribution to its customers as bulk product.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than April 22, 1997.

Dated: February 6, 1997.  
Gene R. Haislip,  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*  
[FR Doc. 97-4346 Filed 2-20-97; 8:45 am]  
BILLING CODE 4410-09-M

**Importation of Controlled Substances; Notice of Application**

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on December 3, 1996, Noramco of Delaware, Inc., Division of McNeilab, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Opium, raw (9600) .....	II
Poppy Straw Concentrate (9670) .....	II

The firm plans to import the listed controlled substances to produce codeine phosphate, codeine sulfate, morphine sulfate, oxycodone and hydrocodone.

Any manufacture holding, or applying for, registration as a bulk manufacturer of these basic classes of controlled substances may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than March 24, 1997.

This procedure is to be conducted simultaneously with and independent

of the procedures described in 21 CFR 1311.42(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import basic classes of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: February 7, 1997.  
Gene R. Haislip,  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*  
[FR Doc. 97-4347 Filed 2-20-97; 8:45 am]  
BILLING CODE 4410-09-M

**DEPARTMENT OF LABOR**

**Occupational Safety and Health Administration**

[Docket No. NRTL-2-93]

**Entela, Inc.; Expansion for Recognition as a Nationally Recognized Testing Laboratory**

**AGENCY:** Occupational Safety and Health Administration, Department of Labor.

**ACTION:** Notice of requests for expansions of recognition as a nationally recognized testing laboratory, and preliminary finding.

**SUMMARY:** This notice announces the applications of Entela, Inc. for expansion of its recognition as a Nationally Recognized Testing Laboratory (NRTL) under 29 CFR 1910.7, for laboratory facilities, test standards, and programs and procedures, and presents the Agency's preliminary finding.

**DATES:** The last date for interested parties to submit comments is April 22, 1997.

**ADDRESSES:** Send comments to: NRTL Recognition Program, Occupational Safety and Health Administration, U.S. Department of Labor—Room N3653, 200 Constitution Avenue, N.W., Washington, DC 20210.

**FOR FURTHER INFORMATION CONTACT:** Office of Variance Determination, NRTL Recognition Program, Occupational Safety and Health Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W., Room N3653, Washington, DC 20210.